Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.

[1]  G. D'Haens,et al.  Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. , 2018, The lancet. Gastroenterology & hepatology.

[2]  S. Fishman,et al.  814 - Phase Iii Randomized Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab in Patients with Active Crohn's Disease: 1-Year Maintenance and Switching Results , 2018 .

[3]  Inge Christoffer Olsen,et al.  815 - Long-Term Efficacy and Safety of CT-P13 after Switching from Originator Infliximab: Exploratory Subgroup Analyses in IBD in the Nor-Switch Extension Trial , 2018 .

[4]  P. Lakatos,et al.  Progress with infliximab biosimilars for inflammatory bowel disease , 2018, Expert opinion on biological therapy.

[5]  M. Neurath,et al.  P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients , 2018 .

[6]  D. Nagore,et al.  P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars , 2018 .

[7]  G. D'Haens,et al.  P545 Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition , 2018 .

[8]  K. Farkas,et al.  Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort , 2017, Inflammatory bowel diseases.

[9]  L. Downey,et al.  Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme , 2017, Journal of Crohn's & colitis.

[10]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[11]  A. Ido,et al.  Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseases , 2017, Alimentary pharmacology & therapeutics.

[12]  S. Bonovas,et al.  The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar , 2017, Inflammatory bowel diseases.

[13]  G. Fiorino,et al.  P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease. , 2017, Journal of Crohn's & Colitis.

[14]  M. Cvancarova,et al.  Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study , 2016, Journal of Crohn's & colitis.

[15]  M. Ferrante,et al.  ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. , 2017, Journal of Crohn's & colitis.

[16]  D. D. de Jong,et al.  Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. , 2016, Journal of Crohn's & colitis.

[17]  M. Lukáš,et al.  Sa1957 Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe , 2016 .

[18]  S. Vermeire,et al.  Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples , 2016, Inflammatory bowel diseases.

[19]  T. Zima,et al.  Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[20]  S. Ben-Horin,et al.  Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima , 2015, Gut.

[21]  M. V. van Oijen,et al.  Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study , 2012, Gut.

[22]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[23]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[24]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[26]  W. Best,et al.  Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). , 1979, Gastroenterology.